Composition :

Each ml NUCOLINE® Injection contain Citicoline soddium equivalent with Citicoline 125 mg


Pharmacology :

Citicoline may increase blood flow and O2 consumption in the brain in the treatment of cerebrovascular disorders so as to correct impaired consciousness. Citicoline has a working mechanism by:

  • Increases the formation reticularis from brain stem, especially the activation system of formatio reticularis ascendens associated with consciousness.
  • Activated pyramidal system and improve motor system paralysis.
  • Increase O2 consumption from brain and improve brain metabolism.


Indication :                                                                                          

  • Acute state :

Loss of consciousness due to cerebral trauma and brain surgery.

Accelerated upper extremity rehabilitation in post apopletic hemiplegia patients: patients with relatively mild limb paralysis who appear within a year and are being rehabilitated and are being given oral drug therapy (with drugs that activate cerebral metabolism or improve circulation).


–     Chronic state :

Neurological and psychiatric disorders (hemiplegia) resulting from apopleksia, head injury and cerebral surgery.


Dosage :

  • For psychological or nervous disorders:

In cases of impaired consciousness in acute stage cerebral infarct: usually given Citicoline 1000 mg once daily I.V. for two weeks.

In post apopletic hemiplegia cases: usually Citicoline 1000 mg is given once daily I.V. for 4 consecutive weeks, and if it appears to be repaired, the administration is continued for another 4 weeks. Intravenous administration should be given slowly.


  • Acute state :

250 – 500 mg, 1 – 2 times daily given by drip I.V. or injection I.V.

Usually 100 to 300 mg, 1-2 times daily intravenously or intramuscularly.

The dosage can be adjusted according to the age and condition patient.


Presentation and Registration Number :

NUCOLINE® 500 mg Injection Box, 5 ampoules @ 4 ml; DKL1208018543A1

NUCOLINE® 1000 mg Injection  Box, 2 ampoulesl @ 8 ml; DKL1208018543A1






Categorised in:

This post was written by admin